Fairvalue-Calculator Fairvalue-Calculator

Jiangsu Sinopep-Allsino Biopharmaceutical Co (688076) Fair Value & Analysis

Healthcare · CN · Market cap 8.6B CNY

Price¥26.74
Fair Value¥22.76
Upside-14.9%
Quality95/100
Evidence: High Range ¥17.07 – ¥28.45

Analysis

Jiangsu Sinopep-Allsino Biopharmaceutical Co (688076) currently trades at ¥26.74, while our model-based Fair Value estimate is ¥22.76 — implying the stock looks roughly 14.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -64% Samsung Biologics Co (207940) +9%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.